Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

British Journal of Pharmacology

Volumn 110, Issue 1, 1993, Pages 245-252

  Wienen, W ^a   Hauel, N ^a   Van Meel, J C A ^a   Narr, B ^a   Ries, U ^a   Entzeroth, M ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Angiotensin II receptor; BIBR 277; losartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; RENIN; TELMISARTAN;

ADRENAL GLAND; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; VASOCONSTRICTION;

ADRENAL MEDULLA; ANGIOTENSIN II; ANIMAL; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DECEREBRATE STATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; HYPERTENSION, RENOVASCULAR; IN VITRO; LUNG; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PEPTIDYL-DIPEPTIDASE A; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; RENIN;

EID: 0027218706     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1993.tb13800.x     Document Type: Article

References (40)

1. Enzyme inhibitors of the renin‐angiotensin system
2. Some quantitative uses of drug agonists
3. Nomenclature for angiotensin receptors
4. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats
5. The role of angiotensin II receptors in vascular regulation
6. 50) of an enzymatic reaction
7. Nonpeptide angiotensin II antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
8. Identification of angiotensin II receptor subtypes
9. Angiotensin II receptors in the rat lung are of the AII‐1 subtype
10. In vitro pharmacology of BIBR 277, a potent and highly selective nonpeptide angiotensin antagonist
11. Direct versus indirect actions of angiotensin in conscious dogs
12. Angiotensin converting enzyme inhibitors. Properties and side effects
13. Drug antagonism
14. Multiple determinants for the high substrate specificity of an angiotensin II‐forming chymase from human heart
15. Evidence that the apparent complexity of receptor antagonism by angiotensin II is due to a reversible and syntopic action
16. Protein measurement with the Folin phenol reagent
17. Action of angiotensins I, II, and III on aldosterone production by isolated rat adrenal zona glomerulosa cells. Importance of metabolism and conversion of peptides in‐vitro
18. Drug concentration response in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
19. Sensitive colorometric assay for angiotensin converting enzyme in serum
20. Different distribution of two types of angiotensin II‐generating enzymes in the aortic wall
21. Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts
22. Role of the pressor action of angiotensin II in experimental hypertension
23. Renin‐angiotensin system: biochemistry and mechanism of action
24. Functions of angiotensin in the central nervous system
25. Converting enzyme inhibitors in the treatment of hypertension
26. 1 receptor antagonist
27. The attraction of proteins for small molecules and ions
28. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition
29. In‐vivo pharmacology of L‐158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist
30. The renin‐angiotensin system
31. Antihypertensive effects of the angiotensin receptor antagonist BIBR 277 in conscious renal hypertensive and spontaneously hypertensive rats
32. Preliminary characterization of two angiotensin II receptor subtypes
33. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
34. Losartan (DuP 753), an orally active nonpeptide angiotensin II receptor antagonist
35. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
36. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DUP 753, an orally active antihypertensive agent
37. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent
38. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753
39. Angio‐oedema and urticaria associated with angiotensin converting enzyme inhibitors
40. Treatment of essential hypertension with combined vasodilation and beta‐adrenergic blockade